Paper Details

  1. Home
  2. Paper Details

Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s).

Author: , AcostaEdward P, CliffordDavid B, EvansScott, GulickRoy M, RibaudoHeather, YangYijun

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

In patients continuing EFV-based regimens for more than 3 years, neuropsychological performance improved from baseline and was maintained. However, small increases in EFV-associated symptoms, bad dreams, and anxiety were observed.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Efavirenz (EFV) is an antiretroviral (ARV) drug associated with neuropsychological effects. Limited data describing the long-term impact of EFV-based regimens on neuropsychological performance over more than 3 years are available. METHODS: We enrolled a subset of participants from a lar...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/20133265

データ提供：米国国立医学図書館（NLM）

Long-Term Neuropsychological Impact of Efavirenz: A 3-Year Study

Efavirenz (EFV), an antiretroviral drug used to treat HIV, is known to have potential neuropsychological side effects. This study aimed to investigate the long-term impact of EFV on neuropsychological performance in HIV-infected individuals over a 3-year period. The researchers followed a cohort of participants from a previous EFV-based treatment study, assessing neuropsychological performance and EFV-associated symptoms over time. Their findings showed that EFV-based treatment generally remained well-tolerated, with no significant deterioration in neuropsychological performance over the 3-year period.

Long-Term Management of HIV: Assessing EFV's Impact

This study provides valuable insights into the long-term impact of EFV-based treatment for HIV. While it demonstrates the general safety and efficacy of EFV in maintaining neuropsychological function over an extended period, the study also highlights the potential for subtle increases in EFV-associated symptoms. These findings underscore the importance of ongoing monitoring and management of potential side effects in patients receiving EFV therapy.

Navigating the Desert of HIV Treatment

This research is like a guidebook for navigating the vast desert of HIV treatment. EFV, like a reliable camel, can carry us through this challenging journey, but it's essential to be aware of potential side effects, like the shifting sands that can create unexpected challenges. This study highlights the importance of ongoing vigilance and monitoring during long-term HIV treatment.

Dr. Camel's Conclusion

Imagine a long caravan journey across a desolate desert, representing the challenges of managing HIV. EFV, like a sturdy camel, can help us navigate this terrain, offering relief and stability. However, it's important to be aware of the potential for shifting sands, like EFV-associated symptoms, and to have a plan in place to address them. This research underscores the importance of a cautious and vigilant approach to managing HIV treatment.

Date :
  1. Date Completed 2010-03-31
  2. Date Revised 2022-03-16
Further Info :

Pubmed ID

20133265

DOI: Digital Object Identifier

NIHMS238774

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.